Lucid Diagnostics(LUCD) - 2025 Q4 - Annual Results

Financial Performance - Processed 3,664 EsoGuard tests and recognized revenue of $1.5 million for Q4 2025[9] - Total revenue for the year ended December 31, 2025, was $4.706 million, compared to $4.346 million in 2024[10] - GAAP net loss attributable to common stockholders was approximately $16.3 million, or $(0.12) per share for Q4 2025[10] - Non-GAAP adjusted loss for Q4 2025 was approximately $12.6 million, or $(0.10) per share[9] - Operating expenses for Q4 2025 were approximately $15.5 million, including stock-based compensation of $1.2 million[9] Business Development - Awarded a contract by the U.S. Department of Veterans Affairs for EsoGuard, expanding access to approximately nine million veterans[9] - The company aims to deepen relationships with the VA and expand adoption across health systems in 2026[5] - The company expects to secure Medicare coverage in the near term[5] Product Performance - EsoGuard achieved a 95% technical success rate in real-world data from nearly 12,000 at-risk patients[9] Cash Position - Cash and cash equivalents as of December 31, 2025, were $34.7 million, up from $22.4 million a year earlier[9]